6. BIBLIOGRAFIA
1 Busnardo B, De Vido D. The epidemiology and etiology of differentiated thyroid carcinoma. Blomed&Pharmacother 2000;54:322-6;
2 Sherman SI, Brierley JD, Sperling M, Ain KB, Bibos ST, Cooper DS et al.
Prospective multicenter study of thyroid carcinoma treatment. Cancer 1998;83:1012-21;
3 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables.
Clinical Oncology 22(2010):395-404;
4 Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17-44;
5 Hundhal SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995.
Cancer 1998;83:2638-2648;
6 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428;
7 Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007;13:498-512;
8 Molinaro E, Viola D, Passannanti P, Agate L, Lippi F, Ceccarelli C, Pinchera A, Elisei R. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging 2009;53:490-502;
9 Durante C, Haddy N, Baudin E et al. Long-term out come of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radio-iodine therapy. J Clin Endocrinol Metab 2006; 91:2892-2899;
10 Fugazzola L, Puxeddu E, Avenia N et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literatute. Endocr Relat Cancer 2006;13:455-464;
11 Fugazzola L, Mannavola D, Cirello V et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-243;
12 Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrin Metab 2001;86:1147-1463;
13 Kumar A, Bal CS. Differentiated thyroid cancer. Indian J Pediatr 2003; 70:707- 713;
14 AACE Clinical Practice Guidelines for the diagnosis and management of thyroid nodule. Endocr Pract. 1996;2:78-84;
15 Yeh MW, Demircan O, Ituarte P, Clark OH. False-negative fine-needle aspiration cytology results delay treatment and adversely aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma.
Thyroid 2004;14:207-215;
16 Mazzaferri EL. Radioactive and other treatments and outcomes. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text. 7th ed. New York: JB Lippincott,1996:922-945;
17 Dulgeroff AJ, Herhman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev. 1994;15:500-515;
18 Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocrine-Related Cancer 2002;9:227-247;
19 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214;
20 Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging
21 Biscontini G, Possa M et al. Diagnostic modalities in patients affected by differentiated thyroid carcinoma with thyroglobulin levels and total body Iodium- 131 negative: PET/TC use after rec-TSH. Minerva Endocrinol 2004;29:151-60;
22 Ozata M, Suzuky S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
J Clin Endocrin Metab 1994;79:98-105;
23 Società Italiana di Endocrinologia, Associazione Italiana Medicina Nucleare, Associazione Italiana di Fisica in Medicina. Carcinoma differenziato della tiroide.
Linee Guida SIE AIMN AIFM per il trattamento ed il follow-up. Anno 2004;
24 Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126;
25 Heemstra KA et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clinical Endocrinology 2007;66:58-64;
26 Iervasi A, Pilo A, Iervasi G, Zucchelli GC. Il dosaggio della tireoglobulina sierica nel follow-up del tumore differenziato della tiroide: recenti acquisizioni (Rassegna). LigandAssay 13(3)2008:203-213;
27 Schlumberger M, Berg G, Cohen O et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Europ J Endocrinol 2004;150:105-12;
28 Dondi M, Giubbini R. Medicina nucleare nella pratica clinica. Pàtron Editore.
Bologna 2003;
29. Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF&Paineau J. Localization of cervical node metastasis of papillary thyroid carcinoma. World Journal of Surgery 1999;23:970-973;
30 Petrich T, Börner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [18F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med May 2002;Vol.29;No.5:641-647;
31 Shammas A et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. The Journal of Nuclear Medicine.
Vol.48,No.2;February 2007:221-226;
32 Grünwald F, Kälicke T, Feine U et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999 Dec;26(12):1547-52;
33 Wang et al. [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrin Metab 1999;Vol.84;No.7;2291-2302;
34 Hall NC, Kloos R. PET imaging in differentiated thyroid cancer: where does it fit and how we use it?. Arq Bras Endocrinol Metab 2007;51/5;
35 Caleo O et al. Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose. Radiol Med 2008;113:278-288;
36 Frasoldati A, Presenti M et al. Diagnosis of neck recurrence in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-96;
37 Mansi C, Moncayo R, Cuccurullo V et al. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Mol Imaging 2004;48:82-89;
38 Jeong H, Baek C, Baek H et al. Integrated 18F-FDG-PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma:
comparison with ultrasound and contrast-enhanced CT. Clinical Endocrinology
39 Volterrani D, Erba PA, Mariani G. Fondamenti di medicina nucleare-tecniche e applicazioni. Springer 2010;
40 Filkelstein et al. Combined [18F] Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for detection of recurrent,131I-negative thyroid cancer. Ann Surg Oncol 2008;Vol.15;No.1:286- 292;
41 Giorgetti A, Volterrani D, Mariani G. Clinical oncological applications of Positron Emission Tomography (PET) using Fluorine-18-Fluoro-2-deoxy-D-glucose. Radiol Med;2002;April;103:293-318
42 Boerner AR, Weckesser M, Herzog H et al. Optimal scan time for fluorine-18 fluorodeoxyglucose Positron Emission Tomography in breast cancer. Eur J Nucl Med 1999;26:226-230;
43 Nakamoto Y, Higashi T, Sakahara H et al. Delayed 18F-Fluoro-2-Deoxy-D- Glucose Positron Emission Tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;December 15;
Vol.89;No.12:2547-2554;
44 Som P, Atkins HL, Bandoypadhyay D et al. A Fluorinated Glucose Analog, 2- fluoro-2-deoxy-D-glucose (F-18): Nontoxic Tracer for Rapid Tumor Detection. J Nucl Med 1980;Vol.21:670-675;
45 Lynch TB. PET-TC nella pratica clinica. Springer 2008;
46 Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-Fluorodeoxyglucose and Positron Emission Tomography: review and 1999 EORTC recommendations. European Organization of Research Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;Dec;35(13):1773-82;
47 Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME:
A tabulated Summary of FDG PET Literature. J Nucl Med 2011;42:1S-93S;
48 Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med 2001; Nov; Vol.28(11):1707-23;
49 Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 1987;120:2576-2581;
50 Vera P et al. Does Recombinant Human Thyrotropin-Stimulated Positron Emission Tomography with [18F]Fluoro-2-deoxy-D-Glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid 2010;Vol.20;No.1:15-23;
51 Ladenson PW, Braverman LE, Mazzaferri EL et al. Comparison of administration of Recombinant Human Thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-896;
52 Ladenson PW. Recombinant Thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000;30:98-106;
53 Matthaei S, Trost B, Hamann A et al. Effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT2 glucose transport systems in rat adipocytes. J Endocrinol 1995;144:347-357;
54 Lazar V, Bidart JM, Caillou B et al. Expression of the Na1/I2 symporter gene in human thyroid tumors: a comparison study with other thyroid specific genes. J Clin Endocrinol Metab 1999;84:3228-3234;
55 Borner AR, Voth E, Wienhard K, Wagner R, Schicha H. 18F-FDG PET in autonomous goiter. Nuklearmedizin 1999;38:1-6;
56 Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
57 Bläser D, Maschauer S, Kuwert T, Prante O. In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-Iodide. J Nucl Med 2006 August;Vol.46;No.8:1382-1388;
58 Ghannam NN, Hammami MM, Muttair Z, Bakheet SM. Primary hypothyroidism- associated TSHsecreting pituitary adenoma/hyperplasia presenting as a bleeding nasal mass and extremely elevated TSH level. J Endocrinol Invest 1999;22:419- 422;
59 Chen YK et al. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun 2007 February;28(2):117-22;
60 Grünwald F, Kalicke T, Feine U et al. Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-1552;
61 Wang W, Macapinlac H, Larson SM et al. [18F]-2-Fluoro-2-Deoxyglucose Positron Emission Tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-2302;
62 Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-Fluoro-2-Deoxy-D-Glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrin Metabol 1993;77:1090-1094;
63 Moog F, Linke R, Manthey N et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-1995;
64 van Tol KM, Jager PL, Piers DA et al. Better yield of 18Fluorodeoxyglucose- Positron Emission Tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-387;
65 Petrich T, Borner AR, Otto D et al. Influence of rhTSH on [18F]Fluoro- deoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-647;
66 Chin BB, Patel P, Cohade C et al. Recombinant Human Thyrotropin stimulation of Fluoro-D-Glucose Positron Emission Tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95;
67 Leboulleux S, Schroeder PR et al. Assessment of the incremental value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94:1310-1316;
68 Oher P, Biersack HJ, Coleman RE. PET and PET-CT in Oncology. Springer-Verlag Ed. Berlin Heidelberg 2004, pag.43;
69 Galanski M, Nagel HD, Stamm G. Radiation Exposure dosage in CT studies:
results of a nationwide inquiry. Rofo 2000;172:M164-168. Erratum in: Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000;172:M197;
70 Koller CJ, Eatough JP, Bettridge A. Variations in radiation dose between the same model of multislice CT scanner at different hospitals. Br J Radiol 2003;76:798-802;
71 Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648;
72 Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]Fluoro-2-deoxy-D-Glucose-Positron Emission Tomography Scanning. J Clin Endocrinol Metab. Febraury 2006;91(2):498-505;
73 Bertagna F, Biasiotto G, Orlando E, Bosio G, Giubbini R. Role of 18F- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the Literature. Jpn J Radiol November 2010;28(9):629-36. Epub 2010 November 27;
74 Hammami MM, Alsaihati B, Alahmari S et al. Elevated serum creatinine level in thyroid cancer patients undergoing withdrawal of thyroxine therapy for radioiodine
75 Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by Recombinant Human Thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619–
625;
76 Vitale G, Lupoli G, Ciccarelli A et al. The use of Recombinant Human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 2001;56:247–252.
